LENZ Therapeutics, Inc. (LENZ) Income Statement
LENZ 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLENZ revenue and net income
Where LENZ's revenue goes
2025Each bar shows an amount and its share of revenue. LENZ kept −430.3% of revenue as net income.
LENZ profit margins
LENZ growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | +8.4% | — | — |
| Gross profit | — | +7.0% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LENZ quarterly EPS vs estimates
LENZ Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.98).
LENZ income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $19.1M | $0 | $0 | $15.0M | $0 | $0 | $0 |
| Cost of revenue | $705,000 | $58,000 | $2.4M | $8.3M | $734,000 | $121,000 | — |
| Gross profit | $18.4M | −$58,000 | −$2.4M | $15.0M | −$734,000 | −$121,000 | — |
| Research & development | $18.7M | $29.8M | $59.5M | $21.1M | $37.9M | $9.1M | — |
| Sales, general & admin | $91.1M | $28.8M | $12.9M | $4.4M | $2.5M | — | — |
| Total operating expenses | $109.5M | $58.6M | $72.4M | $25.5M | $59.7M | $13.4M | $29,000 |
| Operating income | −$91.1M | −$58.6M | −$72.4M | −$10.5M | −$60.4M | −$13.5M | −$29,000 |
| Interest income | $9.8M | $8.6M | $2.2M | — | — | — | — |
| Interest expense | — | — | — | — | — | $40,000 | $80,000 |
| Income before taxes | −$81.6M | −$49.8M | −$70.1M | −$10.5M | −$70.8M | −$68.4M | −$109,000 |
| Income taxes | $502,000 | $1,000 | −$179,000 | $347,000 | $497,442 | — | −$171,860 |
| Net income | −$82.1M | −$49.8M | −$70.0M | −$10.8M | −$70.8M | −$68.4M | −$109,000 |
| EBITDA | −$81.3M | −$49.7M | −$70.1M | −$10.5M | −$70.0M | −$68.2M | $142,860 |
| EPS (diluted) | −$2.81 | −$4.77 | −$10.44 | −$12.95 | −$27.00 | −$8.24 | — |
| Gross margin | 96.3% | — | — | 100.0% | — | — | — |
| Operating margin | −477.5% | — | — | −69.9% | — | — | — |
| Net margin | −430.3% | — | — | −72.1% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.5M | $1.9M | $1.6M | $12.5M | $5.0M | $0 | $66,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $280,000 | $1.2M | $525,000 | $125,000 | $19,000 | $36,000 | $33,000 | $10,000 | $18,000 | $5,000 | $142,000 | $800,000 |
| Gross profit | $5.2M | $714,000 | $1.1M | $12.4M | $5.0M | −$36,000 | $33,000 | −$10,000 | −$18,000 | −$5,000 | −$142,000 | −$800,000 |
| Research & development | $0 | $0 | $0 | $3.8M | $9.1M | $5.8M | $5.9M | $6.5M | $6.9M | $10.5M | $19.5M | $17.0M |
| Sales, general & admin | $39.4M | $45.0M | $39.6M | $27.6M | $12.8M | $11.1M | $9.4M | $6.5M | $7.4M | $5.6M | $5.6M | $5.6M |
| Total operating expenses | $39.4M | $44.8M | $39.5M | $31.3M | $21.8M | $16.9M | $15.2M | $12.9M | $14.4M | $16.1M | $25.0M | $19.9M |
| Operating income | −$34.2M | −$44.1M | −$38.5M | −$18.9M | −$16.9M | −$16.9M | −$15.2M | −$12.9M | −$14.4M | −$16.1M | −$25.0M | −$19.9M |
| Interest income | $2.3M | $2.6M | $3.0M | $2.2M | $2.2M | $2.3M | $2.6M | $2.7M | $2.5M | $788,000 | $788,000 | $788,000 |
| Income before taxes | −$31.9M | −$41.5M | −$35.9M | −$16.7M | −$14.4M | −$14.6M | −$12.7M | −$10.2M | −$10.3M | −$16.6M | −$23.9M | −$18.9M |
| Income taxes | $3,000 | — | $2,000 | — | $500,000 | — | $1,000 | $2.7M | — | −$788,000 | −$179,000 | −$788,000 |
| Net income | −$31.9M | −$41.5M | −$35.9M | −$16.7M | −$14.9M | −$14.6M | −$12.7M | −$10.2M | −$10.3M | −$16.6M | −$23.7M | −$18.9M |
| EBITDA | −$31.8M | −$41.4M | −$35.8M | −$16.6M | −$14.4M | −$14.6M | −$12.6M | −$10.2M | −$10.2M | −$16.6M | −$23.9M | −$18.9M |
| EPS (diluted) | −$1.02 | −$1.32 | −$1.16 | −$0.59 | −$0.53 | −$0.53 | −$0.46 | −$0.38 | −$0.40 | −$3.53 | −$0.40 | −$0.24 |
| Gross margin | 94.9% | 37.6% | 66.9% | 99.0% | 99.6% | — | 50.0% | — | — | — | — | — |
| Operating margin | −622.9% | −2,321.7% | −2,422.1% | −151.1% | −337.1% | — | −23,068.2% | — | — | — | — | — |
| Net margin | −581.8% | −2,182.4% | −2,260.5% | −133.6% | −298.2% | — | −19,169.7% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LENZ's financial statements (latest annual report filed March 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LENZ financial results
In fiscal year 2025 (ended December 31, 2025), LENZ Therapeutics reported revenue of $19.1 million. It had a net loss of $82.1 million, a net profit margin of −430.3%. Diluted earnings per share came to −$2.81.
See the LENZ stock overview for the latest quote and news, or the LENZ chart for price history and technical indicators.
LENZ income statement FAQ
What is LENZ Therapeutics's annual revenue?
LENZ Therapeutics reported total revenue of $19.1 million for fiscal year 2025, which ended on December 31, 2025.
Is LENZ Therapeutics profitable?
No. LENZ Therapeutics reported a net loss of $82.1 million in fiscal 2025, a net profit margin of −430.3%; its operating margin was −477.5%.
What is LENZ Therapeutics's gross margin?
LENZ Therapeutics's gross margin was 96.3% in fiscal 2025: for every $100 of revenue, LENZ Therapeutics kept $96 after the direct cost of its products and services.
How much does LENZ Therapeutics spend on research and development?
LENZ Therapeutics spent $18.7 million on research and development in fiscal 2025, 97.8% of revenue.
What are LENZ Therapeutics's earnings per share?
LENZ Therapeutics earned $-2.81 per diluted share in fiscal 2025, compared with $-4.77 a year earlier.
When will LENZ Therapeutics report its next earnings?
LENZ Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does LENZ Therapeutics's fiscal year end?
LENZ Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 24, 2026.